This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Université de Montréal directory, so their courses and email address may be missing. Find their university profile.
Research
Latest papers
ATM c.7374_7375insAlu is a French-Canadian founder pathogenic variant associated with predisposition to pancreatic and breast cancer.
Journal of medical genetics · 2026
Author Correction: Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial.
Nature medicine · 2024
Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial.
Nature medicine · 2023
Latest funding
- $696,150
Targeting interleukin-22 through dietary supplementation to control gut inflammation, tumorigenesis, and microbiota homeostasis
CIHR · 2024 · Co-investigator
- $250,000
Leveraging liquid biopsies to improve detection of primary and recurrent breast cancer
SSHRC · 2023 · Co-investigator
- $50,000
COVID-19 Variant Supplement - Development of Vaccines to Prevent SARS-CoV-2 Infection of High Risk Individuals
CIHR · 2021 · Principal investigator
5 publications.
ATM c.7374_7375insAlu is a French-Canadian founder pathogenic variant associated with predisposition to pancreatic and breast cancer.
Wang Y, Domecq C, Cuggia A, Mejia-Garcia A, Romero JM, Hamel N, Lapointe R, Provencher D, Mes-Masson AM, Tonin PN, Gravel S, Zogopoulos G, Foulkes WD
Author Correction: Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial.
Routy B, Lenehan JG, Miller WH, Jamal R, Messaoudene M, Daisley BA, Hes C, Al KF, Martinez-Gili L, Punčochář M, Ernst S, Logan D, Belanger K, Esfahani K, Richard C, Ninkov M, Piccinno G, Armanini F, Pinto F, Krishnamoorthy M, Figueredo R, Thebault P, Takis P, Magrill J, Ramsay L, Derosa L, Marchesi JR, Parvathy SN, Elkrief A, Watson IR, Lapointe R, Segata N, Haeryfar SMM, Mullish BH, Silverman MS, Burton JP, Maleki Vareki S
Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial.
Routy B, Lenehan JG, Miller WH, Jamal R, Messaoudene M, Daisley BA, Hes C, Al KF, Martinez-Gili L, Punčochář M, Ernst S, Logan D, Belanger K, Esfahani K, Richard C, Ninkov M, Piccinno G, Armanini F, Pinto F, Krishnamoorthy M, Figueredo R, Thebault P, Takis P, Magrill J, Ramsay L, Derosa L, Marchesi JR, Parvathy SN, Elkrief A, Watson IR, Lapointe R, Segata N, Haeryfar SMM, Mullish BH, Silverman MS, Burton JP, Maleki Vareki S
High-dimensional analysis of the adenosine pathway in high-grade serous ovarian cancer.
Bareche Y, Pommey S, Carneiro M, Buisseret L, Cousineau I, Thebault P, Chrobak P, Communal L, Allard D, Robson SC, Mes-Masson AM, Provencher D, Lapointe R, Stagg J
A Randomized Controlled Study to Evaluate the Safety and Reactogenicity of a Novel rVLP-Based Plant Virus Nanoparticle Adjuvant Combined with Seasonal Trivalent Influenza Vaccine Following Single Immunization in Healthy Adults 18-50 Years of Age.
Langley J, Pastural E, Halperin S, McNeil S, ElSherif M, MacKinnon-Cameron D, Ye L, Grange C, Thibodeau V, Cailhier JF, Lapointe R, McElhaney J, Martin L, Bolduc M, Laliberté-Gagné ME, Leclerc D, Savard P
Targeting interleukin-22 through dietary supplementation to control gut inflammation, tumorigenesis, and microbiota homeostasis
Principal investigators: Santos, Manuela M
Keywords: Acetate; Colorectal Cancer; Il-22; Inflammation; Microbiota; Postbiotics; Probiotics; Putrescine
Leveraging liquid biopsies to improve detection of primary and recurrent breast cancer
Principal investigators: Hassan, Saima
COVID-19 Variant Supplement - Development of Vaccines to Prevent SARS-CoV-2 Infection of High Risk Individuals
Principal investigators: Bell, John C; Ilkow, Carolina S; Lapointe, Réjean; Mahoney, Douglas J
Keywords: Covid-19; Epitopes; Immunity; Infection; Manufacturing; Pre-Clinical; Sars-Cov-2; Vaccine
Development of Vaccines to Prevent SARS-CoV-2 Infection of High Risk Individuals
Principal investigators: Bell, John C; Ilkow, Carolina S; Lapointe, Réjean; Mahoney, Douglas J
Keywords: Covid-19; Epitopes; Immunity; Infection; Manufacturing; Pre-Clinical; Sars-Cov-2; Vaccine
Étude de la modulation inflammatoire induite par les cristalloïdes chez les sujets sains et les patients de soins critiques
Principal investigators: Cailhier, Jean-Francois; Bouchard, Josée
Keywords: Immunomonitoring; Inflammation; Phénotype Leucocytaire; Soins Critiques; Solutés De Type Cristalloïde; Étude Perspective Observationnelle
Deciphering alternative functions of B lymphocytes
Principal investigators: Lapointe, Réjean
Les Cellules Souches : Mythes, Controverses et Réalité
Principal investigators: Roy, Denis-Claude
Keywords: Cadre Règlementaire; Café Scientifique; Cellules Souches; Cellules Souches Embryonnaires; Enjeux Éthiques; Greffe De Cellules Souches; Immunothérapie Du Cancer; Médecine Régénérative; Réparation Tissulaire; Thérapie Cellulaire
Canadian Cancer Immunotherapy Consortium Symposium 2012
Principal investigators: Lapointe, Réjean
Keywords: Cancer; Clinical Trials; Immunology; Immunotherapy; Trainee Mentorship
Deciphering alternative functions of B lymphocytes
Principal investigators: Lapointe, Réjean
Defining innovating cancer vaccine based on virus-like particles by targeting multiple antigens
Principal investigators: Lapointe, Réjean
Keywords: Cancer Vaccine; Melanoma; Mhc Class I; Papaya Mosaic Virus; Vaccine Development; Virus-Like Particle
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
- Bertrand Routy and Arielle Elkrief: 33 shared papers
- Shelly McNeil and Joanne Langley: 3 shared papers
- Simon Gravel and Anne-Marie Mes-Masson: 3 shared papers
- John Stagg and Anne-Marie Mes-Masson: 3 shared papers
- John Stagg and Bertrand Routy: 3 shared papers
- Scott Halperin and Shelly McNeil: 2 shared papers
- Scott Halperin and Joanne Langley: 2 shared papers
- Anne-Marie Mes-Masson and Réjean Lapointe: 2 shared papers
- Bertrand Routy and Réjean Lapointe: 2 shared papers
- Arielle Elkrief and Réjean Lapointe: 2 shared papers
- Scott Halperin and Denis Leclerc: 1 shared paper
- Scott Halperin and Réjean Lapointe: 1 shared paper
- Shelly McNeil and Denis Leclerc: 1 shared paper
- Shelly McNeil and Réjean Lapointe: 1 shared paper
- Joanne Langley and Denis Leclerc: 1 shared paper
- Joanne Langley and Réjean Lapointe: 1 shared paper
- Denis Leclerc and Réjean Lapointe: 1 shared paper
- Simon Gravel and Réjean Lapointe: 1 shared paper
- John Stagg and Arielle Elkrief: 1 shared paper
- John Stagg and Réjean Lapointe: 1 shared paper
- Pediatrics
- Médecine
- Medicine
- Hematology-Oncology
- Microbiologie, Infectiologie et Immunologie
- Oncology
- Human Genetics
- Other
Co-authors at Université de Montréal, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.
Anne-Marie Mes-Masson
Medicine
2 shared papers, latest 2026
Bertrand Routy
Hematology-Oncology
2 shared papers, latest 2024
Arielle Elkrief
Faculty
2 shared papers, latest 2024
Denis Leclerc
Microbiologie, Infectiologie et Immunologie
1 shared papers, latest 2020
Scott Halperin
Pediatrics
1 shared papers, latest 2020
John Stagg
Oncology
1 shared papers, latest 2021
Simon Gravel
Human Genetics
1 shared papers, latest 2026
Shelly McNeil
Pediatrics
1 shared papers, latest 2020
Joanne Langley
Pediatrics
1 shared papers, latest 2020
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.